secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001493152-24-043851
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences Q3 revenue $12.3M, record test volume, swings to profit
-----------------------------------------------------------------------------

- Q3 net revenue $12.3M, up 35% YoY ($9.1M); test volume up 26% to record levels.
- Operating income $1.9M vs operating loss of $0.02M a year ago; adjusted EBITDA $2.1M vs $0.4M.
- Income from continuing ops $1.4M vs loss of $0.5M; gross margin 61% up from 55%.
- Cash collections $11.3M (+15% YoY); cash $2.1M after $6.6M debt paydown; 18th consecutive quarter of YoY volume growth.
- Company interviewing equity research partners and investment bankers for capital raise and potential Nasdaq listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224043851/0001493152-24-043851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224043851/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer